Abstract: The present invention relates generally to methods of use and compositions useful for treating skin. The composition includes a combination of one or more of Butyrospermum parkii (shea butter), PEG-50 shea butter, glycerin, Helianthus annuus (sunflower) seed oil, Prunus armeniaca (apricot) kernel oil, acrylates copolymer, sodium lauryl sulfate, lauramidopropyl betaine, sodium methyl cocoyl taurate, glycerin, and polyquaternium-7.
Type:
Application
Filed:
December 21, 2017
Publication date:
July 5, 2018
Inventors:
Michael Frushour, Lisha VanPelt, Kim Wilson, Geetha Kalahasti, Kathlene Cummings, Lee Vickers
Abstract: The present invention relates to a cosmetic composition for whitening comprising a Caragana sinica root extract, and more specifically relates to a cosmetic composition having an outstanding skin-whitening effect, the composition comprising a Caragana sinica root extract, a fraction thereof or ?-viniferin isolated therefrom. In the present invention, the Caragana sinica root extract, fraction thereof or ?-viniferin isolated therefrom inhibits tyrosinase activity and suppresses melanin production and is therefore effective in skin whitening.
Type:
Application
Filed:
June 29, 2016
Publication date:
July 5, 2018
Inventors:
Sung Min PARK, Jung No LEE, Hyo Min KIM, Jae Mun KIM, Kwang Jun YOON, Seung Ki LEE, Jae Hun KIM, Yeon Sook KIM, Joo Hyuck LIM, Heyong Mi KIM, Sung Ho MOON
Abstract: This invention comprises a method of transmucosal delivery of process of Vitamin B12 without the need of intrinsic factor comprising administering a solid composition comprising a Vitamin B12 and at least one bifunctional macromolecule with hydrophilic exterior and with hydrophobic pockets capable of pocketing Vitamin B12 material, illustrated by cyclodextrin, at least one permeation enhancer, illustrated by Isopropyl Myristate and at least one agent that is mucoadhessive as well as penetration enhancer, illustrated by chitosan. The solid composition of Vitamin B12 of claim 2 may comprise a lozenge, a candy, a wafer, a tablet, a patch, a film, a spray, a lip balm, or gum.
Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit containing at least 100 ?g of an estetrol component selected from estetrol, estetrol esters and combinations thereof; wherein the solid dosage unit can be obtained by a process that comprises: providing a loading liquid comprising organic solvent; estetrol component and optionally one or more other pharmaceutically acceptable ingredients; mixing 1 part by weight of the loading liquid with 0.5-20 parts by weight of carrier particles to produce wet particles; removing organic solvent from the wet particles to produce loaded particles; optionally mixing the loaded particles with one or more tabletting excipients; and forming the loaded particles or the mixture of the loaded particles and the one or more tabletting excipients into a solid dosage unit. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.
Type:
Application
Filed:
June 17, 2016
Publication date:
July 5, 2018
Applicant:
Mithra Pharmaceuticals S.A.
Inventors:
Séverine Francine Isabelle JASPART, Johannes Jan PLATTEEUW, Denny Johan Marjin VAN DEN HEUVEL
Abstract: The present disclosure is directed to fatty-acid glycerol ester derivative compounds containing a targeting bisphosphonate group. The disclosure further include pharmaceutical or biomedical compositions comprising these compounds, and methods of using these compounds and compositions forming microbubbles. The microbubbles have affinity for metal-containing, especially calcium-containing, bodies and/or biological targets. In certain embodiments, these compositions are useful for providing targeted placement of microbubbles capable of cavitation on application of high frequency energy.
Abstract: The present invention provides a core-shell structure having high skin permeability. The core-shell structure includes a core portion containing a hydrophilic drug having a molecular weight of 400 or more; and a shell portion containing a surfactant, and the core portion is a solid, the hydrophilic drug has a water-octanol partition coefficient of ?3 or more and 6 or less, the surfactant has an alkyl group or an alkenyl group having 10 to 20 carbon atoms, and a mass ratio between the hydrophilic drug and the surfactant (hydrophilic drug:surfactant) is 1:5 to 1:20.
Abstract: A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.
Abstract: A liquid crystalline drug delivery system for ocular administration. The drug delivery system, which is mucoadhesive, biocompatible, non-irritating, and tissue permeable, contains nanoparticles stably dispersed in an aqueous solution and can be formulated for sustained release. Also provided are methods for producing the drug delivery system and methods for treating ocular disorders by administering it to a subject.
Type:
Application
Filed:
February 27, 2018
Publication date:
July 5, 2018
Inventors:
Shikha P. Barman, Kevin L. Ward, Anne-Marie Cromwick, Koushik Barman, Ritesh V. Thekkedath
Abstract: The present inventor has discovered how to adsorb a mitochondrially targeted compound (MTC) of general formula I on contact lenses and other matrices prior the application of lenses or other matrix on the eye surface. After such matrix is positioned on eye, MTC is translocated from lens into cornea cells of the eye providing cornea protective effect and thus reducing side effects of contact lens application.
Abstract: Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.
Type:
Application
Filed:
December 6, 2017
Publication date:
July 5, 2018
Applicant:
Dr. Falk Pharma GmbH
Inventors:
Roland Greinwald, Ralph Mueller, Markus Proels, Rudolf Wilhelm
Abstract: Described herein are methods of use of purified preen oil, food and feed compositions containing purified preen oil, food and feed additives containing purified preen oil, and pharmaceutical compositions containing purified preen oil. Methods include treatment of chronic joint inflammation in humans and animals by orally administering purified preen oil. Also included are methods of feeding a growing fish by feeding the feeding the growing fish purified preen oil in amounts effective to improve survival and/or stimulate growth in the growing fish. Further included are methods of feeding live prey organisms purified preen oil, and feeding the live prey organisms to growing fish.
Type:
Application
Filed:
February 27, 2018
Publication date:
July 5, 2018
Inventors:
MARK E. COOK, JORDAN SAND, JAKE M. OLSON, TERENCE P. BARRY
Abstract: Provided herein are pharmaceutical compositions comprising nitrogen mustard, for example bendamustine hydrochloride, solid dispersions substantially free of degradants. Also provided are methods of producing and administering nitrogen mustards and in particular bendamustine hydrochloride solid dispersions substantially free of degradants. The pharmaceutical compositions can be used for any disease that is sensitive to treatment with bendamustine hydrochloride, such as neoplastic diseases.
Abstract: The present disclosure relates to emulsions for parenteral administration comprising propofol, wherein the free propofol concentration in the aqueous phase is below 0.1% of the total propofol content. The present disclosure further relates to a method for manufacturing the compositions of the disclosure as well as to the use of the compositions of the disclosure.
Type:
Application
Filed:
June 30, 2016
Publication date:
July 5, 2018
Inventors:
Edmundo Brito De La Fuente, Crispulo Gallegos-Montes, Telli Hekmatara, Lida A. Quinchia-Busta-Mente
Abstract: The present invention provides a carrier containing a first block copolymer and a second block copolymer, wherein the first block copolymer is a block copolymer of a first non-charged segment and a first complex-forming segment, at least some proportion of said first block copolymer is modified by a first molecule, the second block copolymer is a block copolymer of a second non-charged segment and a second complex-forming segment, and wherein at least some proportion of said second block copolymer is modified by a second molecule, said first molecule is a GLUT1 ligand, and said second molecule is different from the first molecule.
Type:
Application
Filed:
July 1, 2016
Publication date:
July 5, 2018
Applicant:
The University of Tokyo
Inventors:
Kazunori KATAOKA, Yasutaka ANRAKU, Mao HORI
Abstract: A oil-in-water curcumin nanoemulsion that includes curcumin dissolved in at least one miscible solvent and encapsulated in an oil core, wherein the oil core also comprises a stabilizer, wherein the oil core forms an organic phase which is dispersed in an aqueous solvent, and wherein the oil core is selected from a pharmaceutically acceptable oil. A method of manufacturing an oil-in-water curcumin nanoemulsion includes dissolving the curcumin in at least one miscible solvent; encapsulating the curcumin in the oil core to produce an organic phase solution; adding the stabilizer to the organic phase solution; dispersing the organic phase solution in the aqueous solvent; and evaporating the mixture. A method of preventing metastatic cancer using an oil-in-water curcumin nanoemulsion by administering an amount of the nanoemulsion topically to an area of an excised primary tumor, and monitoring any reincidence of metastatic cancer in the excised primary tumor area.
Type:
Application
Filed:
December 28, 2017
Publication date:
July 5, 2018
Inventors:
Simón Juan GUERRERO RIVERA, Pamela Paz CONTRERAS ORELLANA, Victor DÍAZ GARCÍA, Pablo Alberto LARA ARENAS, Areli Marly ANDREA, Lisette LEYTON CAMPOS, Marcelo Javier KOGAN BOSIAN, Andrew F.G. QUEST, Felipe Andrés OYARZÚN AMPUERO, Andrea I. VIVANCO PALMA, Víctor Andrés MIRANDA MIRANDA
Abstract: A composition is described that includes adapalene and dispersed benzoyl peroxide to be used in a non-rinse topical application and in the form of a mousse, comprising: at least one intermediate composition; at least one gas-generating agent; at least one agent activating the gas-generating agent; adapalene or one of its salts; and benzoyl peroxide. A kit or single container is also described that can include a plurality of compartments including this composition.
Abstract: The present invention discloses c-MYC-siRNA formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. It is disclosed targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line inducing a significant cell growth arrest and inhibition of cell proliferation. Apoptosis and arrest of cell cycle progression were also observed after c-MYC-siRNA-based silencing of c-MYC. Furthermore, delivering nanoliposomal c-MYC-siRNA, decreased tumor weight and number of tumor nodules compared with a liposomal-negative control siRNA.
Type:
Application
Filed:
February 20, 2018
Publication date:
July 5, 2018
Inventors:
Pablo E. Vivas-Mejia, Jeyshka M. Reyes Gonzalez, Anil K. Sood
Abstract: A composition is provided that comprises a therapeutic agent encapsulated by a milk-derived microvesicle. The compositions can include therapeutic agents such as phytochemical agents or chemotherapeutic agents, while the milk-derived microvesicle can be derived from raw milk or colostrum. Further provided are methods for isolating a microvesicle that includes the steps of obtaining an amount of milk, and subjecting the milk to a series of sequential centrifugations configured to yield greater than about 300 mg of microvesicle protein per 100 ml of milk. Methods of modifying an immune response and treating a cancer in which a milk-derived microvesicle composition is administered are also provided.
Type:
Application
Filed:
March 2, 2018
Publication date:
July 5, 2018
Inventors:
Ramesh C. Gupta, Radha Munagala, Farrukh Aqil, Jeyaprakash Jeyabalan
Abstract: Materials containing pharmaceutically active species in solid (e.g., crystal) form, and related methods, are provided, allowing for improved stability, solubility, bioavailability, and/or dissolution rates for pharmaceutically active species having poor aqueous solubility.
Type:
Application
Filed:
March 31, 2015
Publication date:
July 5, 2018
Applicants:
NOVARTIS PHARMA AG, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Inventors:
Allan Stuart Myerson, Xiaochuan Yang, Marcus O'Mahony, Markus Krumme, Norbert Rasenack, Leia Dwyer
Abstract: A solid dosage form having a matrix with at least one active compound dispersed homogeneously in the matrix, which is obtainable by melting a powder mixture, wherein the powder mixture comprises at least one thermoplastic binder and a combination of highly disperse silica and at least one inorganic pigment, is described. The co-use of the highly disperse silica and the inorganic pigments leads to better flow properties of the powder mixture, has the effect of a faster release of the active compound from the dosage forms obtained, and imparts a visually pleasing appearance to the dosage forms. A process for the preparation of the dosage form is also described.
Abstract: A method of treating a detachment of a retina of an eye, the method including the steps of injecting a substance into a vitreous cavity of the eye, the substance slowing flow of fluid through the vitreous cavity into a subretinal space to reduce a rate of accumulation of a subretinal fluid in the subretinal space to below a rate of removal of the subretinal fluid from the subretinal space by retinal pigment epithelium; and permitting the retinal pigment epithelium to reattach the retina. The invention also includes devices for practicing the method.
Abstract: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. The second layer, which can be adjacent the first layer comprises a pharmaceutically active agent that can be the same or different from the pharmaceutically active agent in the microparticles in the first layer. The composition further comprises a superabsorbent material (for example, polycarbophil) disposed within the first layer, the second layer, or both the first layer and the second layer. When intact, the pharmaceutically active agent is released from the second layer faster than the pharmaceutically active agent in the first layer.
Type:
Application
Filed:
September 11, 2017
Publication date:
July 5, 2018
Inventors:
Miloud Rahmouni, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Ali Bichara
Abstract: A single dosage form that delivers a tripulse (i.e., three pulses) release profile is provided. The dosage form includes at least three dosage units inside the final dosage form. By providing a single dosage form with multiple dosage units, the dosing frequency is decreased since precise blood levels of the active over a prolonged time period are controlled and achieved.
Type:
Application
Filed:
December 22, 2017
Publication date:
July 5, 2018
Applicant:
Cingulate Therapeutics LLC
Inventors:
Matthew Brams, Raul Silva, Arthur Straughn
Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.
Type:
Application
Filed:
February 27, 2018
Publication date:
July 5, 2018
Inventors:
Masanori ITO, Kenji EGUSA, Roman MESSERSCHMID, Peter SCHNEIDER
Abstract: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof.
Abstract: Provided is a bacterium-containing oral rapidly disintegrating tablet excellent in long-term stability of viable bacteria. It has been found that a disintegration time can be shortened and stability of viable bacteria can be improved by using a spray-drying method in a process of granulating viable bacteria.
Abstract: MYCO Capsules are the next wave of innovation in the pharmaceutical industry, by improving individual company spending budget costs, and increasing medication production rates across the world, through giving the user a new digestive medicine method, which will best fit the users diagnosis, anatomy, philosophy, and medicine spending budget. Where reduction costs of medicine aspire, lower health insurance plans will arise. As the cost of health insurance plans decrease, more users will be able to afford health insurance with plans that cover the use of MYCO Capsules.
Abstract: Medicaments and therapeutic compositions comprise Red Yeast Rice extract and omega-3 polyunsaturated fatty acids and/or derivatives thereof, e.g., DHA, derivatives of DHA, EPA, derivatives of EPA or mixtures thereof. One source of the fatty acids or derivatives thereof is fish oil. The compositions are useful for lowering cholesterol and/or triglyceride levels in a subject.
Abstract: Biodegradable microcapsules include a biodegradable polymer shell and filling material. The polymer shell completely encompasses the filling material. The filling material may include one or more biodegradable microparticles or a therapeutic agent or both.
Abstract: An oral transenterocytotic mucosal adhesion vehicle includes a ghost cell formed from fermented bacterium providing a container for uptake and active transport via a lacteal surface and a nano encapsulated drug particle including a bioactive agent which is encapsulated by a polymeric coating disposed within said ghost cell and surviving first pass liver metabolism, wherein the polymeric coating comprises molecules of an alginate and transmucosal delivery enhancing molecules, wherein the transmucosal delivery enhancing molecules are covalently conjugated to the alginate molecules, wherein the polymeric delivery vehicle is resistant to intestinal degradation and wherein the polymeric delivery vehicle is capable of transmucosal passage across the intestinal mucosa into the lymphatic capillary wherein the polymeric delivery vehicle comprising the alginate molecules and transmucosal delivery enhancing molecules covalently conjugated thereto is degraded to release substantially all of the bioactive agent.
Abstract: The present invention relates to use of biphenols in the preparation of a medicament for the prevention and treatment of ischemic stroke, specifically to use of 3,3?,5,5?-tetraisopropyl-4,4?-biphenol and salt, ester, or solvate thereof in the preparation of a medicament for the prevention and treatment of ischemic stroke injury.
Type:
Application
Filed:
March 11, 2016
Publication date:
July 5, 2018
Inventors:
Rutao Wang, Tao Chen, Long An, Yi Zhao, Weijiao Wang, Shupan Guo, Sa Xiao, Jinghua Pang, Huijing Hu
Abstract: The invention provides methods for preventing, ameliorating and treating the acute and chronic forms of graft-versus-host disease (GVHD) by using Cannabidiol compositions.
Abstract: Suggested are compositions comprising or consisting of specific polyalkylene glycol derivative as pharmaceutical actives for preventing, treating and/or curing itchy conditions of human skin and scalp, and/or providing a PAR-2 antagonistic effect to human skin and scalp.
Abstract: In one aspect, a method of treating a subject having or at risk of having a tumor generally includes administering to the subject an amount of a PKC-NFkB axis inhibitor effective to ameliorate at least one symptom or clinical PMA sign of the tumor. In another aspect, a method of treating a subject having a tumor generally includes confirming that APOBEC3B is present in cells of the tumor and administering to the subject an amount of a PKC-NFkB axis inhibitor effective to decrease APOBEC3B in the cells of the tumor.
Abstract: A mechanism of monoamine oxidases (MAOs) driven epithelium-to-mesenchymal transition (EMT) is disclosed. Also disclosed are methods for treating cancer by inhibiting or suppressing MAOs in cancer cells. Novel MAOs inhibitors, such as small molecules, siRNA, shRNA, antisense oligonucleotides, aptamers, decoys, and pharmaceutical compositions useful for treating cancer by disrupting the workings of MAOs are provided. In particular, a class of conjugates formed by covalently conjugating near infrared dye 783, IR-780, and MHI-148 to a MAO inhibitor, such as clorgyline, with and without encapsulation it in a nanoparticle is provided. Other aspects of the invention include methods for forming the nano-conjugates, method for monitoring treatment progress in a cancer patient by monitoring the changes in MAO activity, methods for screening patients who are at risk of cancer or differentiating different forms of cancer by assaying the level and location of MAO activity.
Type:
Application
Filed:
August 28, 2017
Publication date:
July 5, 2018
Applicant:
UNIVERSITY OF SOUTHERN CALIFORNIA
Inventors:
Jean C. SHIH, Leland CHUNG, Haiyen E. ZHAU, Boyang Jason WU, Bogdan Z. OLENYUK
Abstract: This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective combination of Tesofensine and Metoprolol for preventing the cardiovascular side effects of Tesofensine, while leaving the robust inhibitory efficacy on food intake and body weight loss unaffected.
Type:
Application
Filed:
February 27, 2018
Publication date:
July 5, 2018
Inventors:
Henrik Bjork Hansen, Morten Grunnet, Bo Hjorth Bentzen, Lars Hyveled-Nielsen, Jorgen Buus Lassen, Claus Sundgreen
Abstract: The present invention relates to cysteamine, cystamine, or derivatives thereof, for use in the treatment and/or prevention of infection caused by the bacterium, Mycobacterium spp., in particular Mycobacterium abscessus, or a disease or condition associated therewith.
Abstract: Provided are compounds for the treatment of neurological diseases or injuries, including neurodegenerative diseases, stroke, trauma, epilepsy, acute and chronic kidney injuries, diabetes mellitus, and/or seizures. In some embodiments, derivatives of vitamin K are provided.
Type:
Application
Filed:
December 6, 2017
Publication date:
July 5, 2018
Applicant:
MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
Inventors:
C. James CHOU, Sherine S. CHAN, Jennifer J. RAHN, Benjamin J. JOSEY
Abstract: The invention relates to compositions for preventing or delaying the onset of hepatocellular cancer. The compositions of the invention may comprise short chain fatty acids. The compositions of the invention may also comprise probiotic bacteria. The compositions of the invention include compositions for preventing or delaying the onset of hepatocellular cancer by treating or preventing liver inflammation, liver disease, and precancerous lesions.
Type:
Application
Filed:
February 23, 2018
Publication date:
July 5, 2018
Inventors:
Mark A. Feitelson, Helena M.G.P.V. Reis
Abstract: Disclosed are methods of treating anti-inflammatory disease or conditions, typically by orally administering encochleated anti-inflammatory agents, including NSAIDS. Orally administered cochleates have significantly reduced toxicity as compared to non-encochleated anti-inflammatory agents.
Abstract: Provided are compositions and methods for improving podocyte and kidney function and glucose homeostasis in diabetic and pre-diabetic states.
Type:
Application
Filed:
June 2, 2016
Publication date:
July 5, 2018
Applicants:
The Regents of the University of California, United States of America, as Represented by Secretary of Health and Human Services
Inventors:
Bruce D. HAMMOCK, Fawaz G. HAJ, Ahmed BETTAIEB, Darryl C. Zeldin
Abstract: This invention discloses uses for sulindac in preparing anti-lung cancer products. This invention provides uses for sulindac in the preparation of products to treat lung cancer. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug sulindac, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that sulindac has a new use as an anti-lung cancer medication, thus achieving a new purpose for an old drug.
Abstract: Methods and formulations of modified release amino acids are provided for the treatment or management of diseases defined by impaired amino acid metabolism, with improved pharmacokinetics, metabolism and utilization.
Abstract: The present invention provides a composition for preventing or treating immune allergic airway disease, and uses of the composition in preparing drugs, wherein the composition comprises an effective amount of S-allyl-L-cysteine and a pharmaceutically acceptable carrier.
Abstract: Provided is a composition which has high bioabsorbability and excellent biological safety and can enhance an angiotensin-converting enzyme-inhibiting activity ascribable to an amino acid. The ratio of the total amount of an amino acid or a salt thereof to the total amount of a cyclic dipeptide or a salt thereof in the composition is set to within a specific range. This enhances the angiotensin-converting enzyme-inhibiting activity brought about by the amino acid.
Abstract: Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The weight loss agents can also be co-administered with leptin or a leptin analog.
Type:
Application
Filed:
February 28, 2018
Publication date:
July 5, 2018
Inventors:
Umut Ozcan, Joseph Majzoub, Ralph Mazitschek, Isin Cakir, Serkan Cabi
Abstract: Compositions including a fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to anemic conditions, are provided, including compositions and methods for treating anemic conditions such as hemolytic anemia and anemia of chronic disease, and other related conditions.
Abstract: Compositions including an fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to inflammation and conditions related to inflammation, including anemia of chronic disease, insulin resistance, metabolic syndrome, autoimmune disease, hypertension, diabetes, nonalcoholic fatty liver disease, cardiovascular disease, cancer, aging, neurodegenerative diseases, including Alzheimer's disease and other forms of dementia, and other related conditions, and other related conditions.